Ironwood Pharmaceuticals Inc
Closed
SectorHealthcare
4.38 8.68
Overview
Share price change
24h
Min
4.03
Max
4.43
Income | 11M 51M |
|---|---|
Sales | 6.5M 113M |
P/E Sector Avg | 4.553 51.78 |
EPS | 0.31 |
Profit margin | 45.374 |
Employees | 100 |
EBITDA | 6.6M 81M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +48.88% upside |
Market Cap | -156M 572M |
|---|---|
Previous open | -4.3 |
Previous close | 4.38 |
Ironwood Pharmaceuticals Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Ironwood Pharmaceuticals Inc Forecast
Price Target
By TipRanks
48.88% upside
12 Months Forecast
Average 6 USD 48.88%
High 6 USD
Low 6 USD
Based on 1 Wall Street analysts offering 12 month price targets forIronwood Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
